Marijo Bilusic, M.D., Ph.D.
Dr. Bilusic is the Associate Program Director of the Medical Oncology and Hematology Fellowship Program. His current research interests focus on tumor immunology and development of treatment options for prostate cancer and other genitourinary tumors using novel targeted agents, therapeutic cancer vaccines, antibodies, or immune modulators.
Dr. Bilusic's research interests focus on tumor immunology and development of novel immunotherapy approaches for prostate cancer and other genitourinary tumors using therapeutic cancer vaccines, antibodies, or immune modulators. Dr. Bilusic served as a PI or co-investigator on several intramural and industry-sponsored clinical trials and produced several presentations and publications in collaborations with other researchers as an active member of the research team.
Selected Recent Publications
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.Eur Urol. 68(6): 959-67, 2015. [ Journal Article ]
- Asian J Androl. 16(3): 372-7, 2014. [ Journal Article ]
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.Cancer Immunol Immunother. 63(3): 225-34, 2014. [ Journal Article ]
- Semin Oncol. 39(3): 296-304, 2012. [ Journal Article ]
- Cancer Immunol Immunother. 61(1): 109-17, 2012. [ Journal Article ]
Dr. Bilusic completed a clinical fellowship in medical oncology and hematology at the National Cancer Institute and National Heart, Lung, and Blood Institute in Bethesda, MD. In addition, he completed a postdoctoral research fellowship in physiological genomics at the Medical College of Wisconsin's Human and Molecular Genetics Center in Milwaukee, WI. He was an assistant professor (GU medical oncologist) at the Fox Chase Cancer Center/Temple Health from 2012 - 2016.